Postural orthostatic tachycardia syndrome

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
(Redirected from POTS)
This page is available in other languages: español

Postural orthostatic tachycardia syndrome (POTS, or postural tachycardia syndrome) is a condition in which a change from the supine position (lying horizontally) to an upright position causes an abnormally large increase in heart rate, called tachycardia. It is a form of orthostatic intolerance (OI), a type of dysautonomia, which means a dysregulation of the autonomic nervous system (ANS). The autonomic nervous system controls those functions of the body that are considered automatic and involuntary, such as heart rate, blood pressure, respiration, digestion, and arousal. Other symptoms of an orthostatic nature — occurring in response to upright posture — typically accompany the tachycardia.[1] These include, but are not limited to headaches, fatigue, sweating, nausea; fainting and dizziness. The female to male ratio of patients with POTS is 4:1.[2][3]

Onset[edit | edit source]

Onset may be linked to infection including viruses like EBV or enteroviruses, trauma, surgery or stress.[4][5]

Signs and symptoms[edit | edit source]

Acrocyanosis in POTS. These images shows the legs of two patients with POTS, immediately after standing up and after standing for several minutes. The reddish-purple discoloration in the legs is very notable, due to poor circulation in the extremities, which returns to normal upon returning to a reclined position.Source: Abou-Diab, J., Moubayed, D., Taddeo, D., Jamoulle, O., & Stheneur, C. (2018). Acrocyanosis Presentation in Postural Orthostatic Tachycardia Syndrome. International Journal Of Clinical Pediatrics, 7(1-2), 13-16. License: CC-BY-NC 4.0

The main symptom of POTS is an abnormal increase in heart rate upon standing. The specific diagnostic criteria for POTS is a sustained increase in heart rate from the lying to upright position of greater than 40 beats per minute in those ages 12-19 and greater than 30 beats per minute in those ages 20+. There needs to be an absence of significant orthostatic hypotension (magnitude of blood pressure drop ≥ 20/10 mm Hg) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8920526/. Patients with POTS usually present with other symptoms, commonly occurring in the upright position. These include:

Common stimuli in daily life, such as modest exertion, food ingestion and heat, can exacerbate symptoms.[9]

Potential mechanisms[edit | edit source]

Autoimmunity is thought to play a role in many cases of POTS: adrenergic[10], muscarinic[11] and other autoantibodies[12][13][14] have been found. A small study of POTS in children found that 24.39% of patients had acetylcholine receptor autoantibodies.[15]A small study of adult patients found elevated α1, β1 and β2 adrenergic receptor autoantibodies.[16]

Lax vasculature has been though to play a role in the development of POTS in people with Ehlers-Danlos Syndrome, a connective tissue disorder.[17]

Testing[edit | edit source]

Load video
YouTube
This interactive video explains what you can expect during the tilt table test. By eMedTV

Assessing orthostatic blood pressure can be done in a physician's office by measuring the patient's blood pressure while lying down, sitting, and standing at standardized time increments. Dr. Lucinda Bateman uses a modified orthostatic blood pressure assessment called the NASA 10-minute Lean Test, a variant of a test used by NASA researchers to test for orthostatic intolerance following space flight. The NASA 10-minute Lean Test is less taxing on the patient and can be done in any physician's office. Instructions are available for printout for both healthcare providers and patients.[18]

If the results of the standard orthostatic blood pressure assessment are inconclusive, a tilt table test can be used for diagnosis.[19]

Treatment[edit | edit source]

A 2012 study Diagnosis and management of postural orthostatic tachycardia syndrome: A brief review[20] concluded:

"The pathophysiology of POTS is complex and the result of a number of separate mechanisms producing a common pattern of symptoms. The large number of clinical manifestations that characterize this disorder and the wide range of medications available, plus the clear evidence that certain medications and treatment strategies work in some, but not all POTS patients, demonstrates that POTS is a range of disorders requiring comprehensive investigation and characterisation to guide selection of the most appropriate treatment. The recent consensus statement will help to direct further research into the underlying conditions that lead to POTS."
When the cause of POTS is able to be identified and treated in certain individuals, their POTS symptoms may subside. However, there is currently no cure for POTS on the broader level. The following treatments have been identified to improve symptoms and quality of life:

A small randomized crossover design trial found that patients with postural orthostatic tachychardia improved with Mestinon.[22]

Conditions associated with POTS[edit | edit source]

POTS is not only comorbid with a range of diseases, but its phenotype also resembles that of other disorders (e.g., ME, Ehlers-Danlos Syndrome).

ME/CFS[edit | edit source]

POTS can be a co-morbid condition in ME/CFS patients.[23][24] Estimates on the prevalence of POTS among ME/CFS patients varies widely, from 11% to 70%. In a 2008 study done in the UK by the Northern CFS/ME Clinical Network, using the Fukuda criteria, 27% of the study population had POTS compared with 9% in the control population.[25]

Prevalence of POTS in ME/CFS population samples
Study: number of

ME/CFS patients

%

POTS

Stewart et al. 1999 25 70%
Schondorf et al. 1999 75 40%
Hoad et al. 2008 59 27%
Van Campen et al. 2018 627 25%
Dowsett & Ramsay, 1990[26] 420 21%
Lewis et al. 2013 179 13%
Reynolds et al. 2014 306 11%
Roerink et al. 2017 419 5,7%

A 2011 study of 58 POTS patients by the Vanderbilt Autonomic Dysfunction Center (Vanderbilt University School of Medicine, Nashville, TN, U.S.A.), reported that 64% of also met the Centers for Disease Control and Prevention (CDC) criteria for chronic fatigue syndrome.[27]

The SEID criteria requires either orthostatic intolerance (of which POTS is one type) or cognitive dysfunction for a diagnosis.[28] POTS is also a symptom of the Canadian Consensus Criteria (CCC) which diagnoses ME/CFS,[29] and the International Consensus Criteria (ICC) for diagnosing myalgic encephalomyelitis (ME).[30] However, the diagnosis of POTS alone does not automatically support a ME/CFS diagnosis and cannot be used as a diagnostic biomarker to determine ME/CFS. POTS can occur independent from ME/CFS, and, likewise, ME/CFS can occur without the symptomatology of POTS.

A 2016 study in the Netherlands by Roerink et al., found that patients with CFS who fulfilled the SEID criteria did not have a prevalence of POTS different from that in the overall ME/CFS population. In adults with ME/CFS, the prevalence of POTS was low, between 6% - 18% (depending on age), was not different from the rate in non-ME/CFS fatigued patients, and was not related to disease severity or treatment outcome.[31]

ME patients with POTS can experience impaired neurocognitive abilities (such as working memory, information processing) under increased orthostatic stress (i.e., standing, tilt table test).[32]

Other conditions associated with POTS[edit | edit source]

Notable research[edit | edit source]

Learn more[edit | edit source]

See also[edit | edit source]

References[edit | edit source]

  1. ↑ Mar, Philip L.; Raj, Satish R. (2014). "Neuronal and hormonal perturbations in postural tachycardia syndrome". Frontiers in Physiology. 5: 220. doi:10.3389/fphys.2014.00220. ISSN 1664-042X. PMID 24982638.
  2. ↑ "PoTS - Postural Tachycardia Syndrome". PoTS UK. Retrieved August 16, 2018.
  3. ↑ "PoTS - Postural Tachycardia Syndrome - What is POTS?". PoTS UK. Retrieved August 16, 2018.
  4. ↑ Grahame, Rodney; Kirbis, Mojca; Andrew P. Owens; Iodice, Valeria; Low, David A.; Mathias, Christopher J. (January 2012). "Postural tachycardia syndrome—current experience and concepts". Nature Reviews Neurology. 8 (1): 22–34. doi:10.1038/nrneurol.2011.187. ISSN 1759-4766.
  5. ↑ 5.0 5.1 5.2 Gunning, William T.; Kvale, Heather; Kramer, Paula M.; Karabin, Beverly L.; Grubb, Blair P. (September 17, 2019). "Postural Orthostatic Tachycardia Syndrome Is Associated With Elevated G‐Protein Coupled Receptor Autoantibodies". Journal of the American Heart Association. 8 (18): e013602. doi:10.1161/JAHA.119.013602.
  6. ↑ "Symptoms of Postural Orthostatic Tachycardia Syndrome (POTS)". Standing Up to POTS. July 9, 2018.
  7. ↑ Raj, Satish R (April 1, 2006). "The Postural Tachycardia Syndrome (POTS): Pathophysiology, Diagnosis & Management". Indian Pacing and Electrophysiology Journal. 6 (2): 84–99. ISSN 0972-6292. PMC 1501099. PMID 16943900.
  8. ↑ 8.0 8.1 8.2 "Dysautonomia International: Postural Orthostatic Tachycardia Syndrome". dysautonomiainternational.org. Retrieved October 25, 2018.
  9. ↑ 9.0 9.1 Grahame, Rodney; Kirbis, Mojca; Andrew P. Owens; Iodice, Valeria; Low, David A.; Mathias, Christopher J. (January 2012). "Postural tachycardia syndrome—current experience and concepts". Nature Reviews Neurology. 8 (1): 22–34. doi:10.1038/nrneurol.2011.187. ISSN 1759-4766.
  10. ↑ Kem, David C.; Melander, Olle; Sutton, Richard; Scofield, Robert Hal; Quadri, Syed M.S.; Murphy, Taylor A.; Liles, Campbell; Harris, Valerie M.; Koelsch, Kristi A. (July 1, 2017). "Antiadrenergic autoimmunity in postural tachycardia syndrome". EP Europace. 19 (7): 1211–1219. doi:10.1093/europace/euw154. ISSN 1099-5129.
  11. ↑ Yu, Xichun; Stavrakis, Stavros; Hill, Michael A.; Huang, Shijun; Reim, Sean; Li, Hongliang; Khan, Muneer; Hamlett, Sean; Cunningham, Madeleine W. (January 1, 2012). "Autoantibody activation of beta-adrenergic and muscarinic receptors contributes to an "autoimmune" orthostatic hypotension". Journal of the American Society of Hypertension. 6 (1): 40–47. doi:10.1016/j.jash.2011.10.003. ISSN 1933-1711.
  12. ↑ Thieben, Mark J.; Sandroni, Paola; Sletten, David M.; Benrud-Larson, Lisa M.; Fealey, Robert D.; Vernino, Steven; Low, Phillip A.; Lennon, Vanda A.; Shen, Win-Kuang (March 1, 2007). "Postural Orthostatic Tachycardia Syndrome: The Mayo Clinic Experience". Mayo Clinic Proceedings. 82 (3): 308–313. doi:10.4065/82.3.308. ISSN 0025-6196.
  13. ↑ Li Hongliang; Yu Xichun; Liles Campbell; Khan Muneer; Vanderlinde‐Wood Megan; Galloway Allison; Zillner Caitlin; Benbrook Alexandria; Reim Sean. "Autoimmune Basis for Postural Tachycardia Syndrome". Journal of the American Heart Association. 3 (1): e000755. doi:10.1161/JAHA.113.000755. PMC 3959717. PMID 24572257.
  14. ↑ Lennon, Vanda; Low, Phillip; Klein, Christopher; Singer, Wolfgang (April 6, 2015). "Autoantibodies in the Postural Tachycardia Syndrome (P1.272)". Neurology. 84 (14 Supplement): P1.272. ISSN 0028-3878.
  15. ↑ Li, Jiawei; Zhang, Qingyou; Liao, Ying; Zhang, Chunyu; Hao, Hongjun; Du, Junbao (August 3, 2014). "The Value of Acetylcholine Receptor Antibody in Children with Postural Tachycardia Syndrome". Pediatric Cardiology. 36 (1): 165–170. doi:10.1007/s00246-014-0981-8. ISSN 0172-0643.
  16. ↑ Li, Hongliang; Yu, Xichun; Liles, Campbell; Khan, Muneer; Vanderlinde‐Wood, Megan; Galloway, Allison; Zillner, Caitlin; Benbrook, Alexandria; Reim, Sean (January 27, 2014). "Autoimmune Basis for Postural Tachycardia Syndrome". Journal of the American Heart Association. 3 (1). doi:10.1161/jaha.113.000755. ISSN 2047-9980. PMC 3959717. PMID 24572257.
  17. ↑ Hakim, Alan; O'Callaghan, Chris; Wandele, Inge De; Stiles, Lauren; Pocinki, Alan; Rowe, Peter (2017). "Cardiovascular autonomic dysfunction in Ehlers–Danlos syndrome—Hypermobile type". American Journal of Medical Genetics Part C: Seminars in Medical Genetics. 175 (1): 168–174. doi:10.1002/ajmg.c.31543. ISSN 1552-4876.
  18. ↑ Bateman, Lucinda (September 27, 2016). "Simple Way to Assess Orthostatic Intolerance - Bateman Horne Center". Bateman Horne Center Newsletter. Retrieved August 16, 2018.
  19. ↑ "How Doctors Diagnose & Test for POTS". MyHeart. Retrieved August 16, 2018.
  20. ↑ 20.0 20.1 Abed, Howraa; Ball, Patrick A; Wang, Le-Xin (2012). "Diagnosis and management of postural orthostatic tachycardia syndrome: A brief review". Journal of Geriatric Cardiology : JGC. 9 (1): 61–67. doi:10.3724/SP.J.1263.2012.00061. ISSN 1671-5411. PMID 22783324.
  21. ↑ Miller, Amanda J.; Bourne, Kate M. (July 21, 2020). "Abdominal Compression as a Treatment for Postural Tachycardia Syndrome". Journal of the American Heart Association. 9 (14): e017610. doi:10.1161/JAHA.120.017610. ISSN 2047-9980. PMC 7660708. PMID 32673524.
  22. ↑ Raj, S.R. (May 31, 2005). "Acetylcholinesterase Inhibition Improves Tachycardia in Postural Tachycardia Syndrome". Circulation. 111 (21): 2734–2740. doi:10.1161/circulationaha.104.497594. ISSN 0009-7322.
  23. ↑ "POTS in ME/CFS". Freedom From ME - The Optimum Health Clinic on YouTube. August 2, 2014.
  24. ↑ "Overlapping Conditions – American ME and CFS Society". ammes.org. Retrieved August 12, 2018.
  25. ↑ 25.0 25.1 Hoad, A.; Spickett, G.; Elliott, J.; Newton, J. (2008). "Postural orthostatic tachycardia syndrome is an under-recognized condition in chronic fatigue syndrome". QJM: monthly journal of the Association of Physicians. 101 (12): 961–965. doi:10.1093/qjmed/hcn123. ISSN 1460-2393. PMID 18805903.
  26. ↑ Dowsett, E. G.; Ramsay, A.M.; McCartney, R.A.; Bell, E.J. (July 1990). "Myalgic encephalomyelitis--a persistent enteroviral infection?". Postgraduate Medical Journal. 66 (777): 526–530. ISSN 0032-5473. PMC 2429637. PMID 2170962.
  27. ↑ Okamoto, Luis E.; Raj, Satish R.; Peltier, Amanda; Gamboa, Alfredo; Shibao, Cyndya; Diedrich, André; Black, Bonnie K.; Robertson, David; Biaggioni, Italo (February 1, 2012). "Neurohumoral and haemodynamic profile in postural tachycardia and chronic fatigue syndromes". Clinical Science (London, England : 1979). 122 (Pt 4): 183–192. doi:10.1042/CS20110200. ISSN 0143-5221. PMID 21906029.
  28. ↑ Institute of Medicine (March 16, 2015). Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness. Washington, DC: The National Academies Press. Box 4-3, p 114. doi:10.17226/19012 – via NAP.edu.
  29. ↑ "Canadian Consensus Criteria - MEpedia". me-pedia.org. Retrieved August 16, 2018.
  30. ↑ "International Consensus Criteria - MEpedia". me-pedia.org. Retrieved August 16, 2018.
  31. ↑ Roerink, M. E.; Lenders, J. W.M.; Schmits, I.C.; Pistorius, A.M.A.; Smit, J.W.; Knoop, H.; van der Meer, J.W.M. (October 2, 2016). "Postural orthostatic tachycardia is not a useful diagnostic marker for chronic fatigue syndrome". Journal of Internal Medicine. 281 (2): 179–188. doi:10.1111/joim.12564. ISSN 0954-6820.
  32. ↑ Ocon, Anthony J.; Messer, Zachary R.; Medow, Marvin S.; Stewart, Julian M. (March 2012). "Increasing orthostatic stress impairs neurocognitive functioning in chronic fatigue syndrome with postural tachycardia syndrome". Clinical Science (London, England : 1979). 122 (5): 227–238. doi:10.1042/CS20110241. ISSN 0143-5221. PMC 3368269. PMID 21919887.
  33. ↑ "Overlapping Conditions - American Myalgic Encephalomyelitis and Chronic Fatigue Syndrome Society". ammes.org. Retrieved August 12, 2018.
  34. ↑ Yun, Dong Joo; Choi, Han Na; Oh, Gun-Sei (2013). "A Case of Postural Orthostatic Tachycardia Syndrome Associated with Migraine and Fibromyalgia". The Korean Journal of Pain. 26 (3): 303–306. doi:10.3344/kjp.2013.26.3.303. ISSN 2005-9159. PMID 23862007.
  35. ↑ Weig, Spencer G.; Buckthal, Paul E.; Choi, Samuel K.; Zellem, Ronald T. (October 1, 1991). "Recurrent syncope as the presenting symptom of Arnold‐Chiari malformation". Neurology. 41 (10): 1673–1673. doi:10.1212/WNL.41.10.1673. ISSN 0028-3878. PMID 1922816.
  36. ↑ Prilipko, O.; Dehdashti, A.R.; Zaim, S.; Seeck, M. (July 1, 2005). "Orthostatic intolerance and syncope associated with Chiari type I malformation". Journal of Neurology, Neurosurgery & Psychiatry. 76 (7): 1034–1036. doi:10.1136/jnnp.2004.048330. ISSN 0022-3050. PMID 15965223.
  37. ↑ Kanjwal, Khalil; Karabin, Beverly; Kanjwal, Yousuf; Grubb, Blair P. (2011). "Postural orthostatic tachycardia syndrome following Lyme disease". Cardiology Journal. 18 (1): 63–66. ISSN 1897-5593. PMID 21305487.
  38. ↑ Kasmani, Rahil; Elkambergy, Hossam; Okoli, Kelechi (September 2009). "Postural Orthostatic Tachycardia Syndrome Associated With Mycoplasma pneumoniae". Infectious Diseases in Clinical Practice. 17 (5): 342–343. doi:10.1097/IPC.0b013e318191781b. ISSN 1056-9103.
  39. ↑ Kanjwal, Khalil; Karabin, Beverly; Kanjwal, Yousuf; Saeed, Bilal; Grubb, Blair P. (October 2010). "Autonomic dysfunction presenting as orthostatic intolerance in patients suffering from mitochondrial cytopathy". Clinical Cardiology. 33 (10): 626–629. doi:10.1002/clc.20805. ISSN 1932-8737. PMID 20960537.
  40. ↑ Raj, Satish R (April 1, 2006). "The Postural Tachycardia Syndrome (POTS): Pathophysiology, Diagnosis & Management". Indian Pacing and Electrophysiology Journal. 6 (2): 84–99. ISSN 0972-6292. PMC 1501099. PMID 16943900.
  41. ↑ Garland, Emily M; Celedonio, Jorge E; Raj, Satish R (September 2015). "Postural Tachycardia Syndrome: Beyond Orthostatic Intolerance". Current neurology and neuroscience reports. 15 (9): 60. doi:10.1007/s11910-015-0583-8. ISSN 1528-4042. PMC 4664448. PMID 26198889.
  42. ↑ Abed, Howraa; Ball, Patrick A; Wang, Le-Xin (2012). "Diagnosis and management of postural orthostatic tachycardia syndrome: A brief review". Journal of Geriatric Cardiology : JGC. 9 (1): 61–67. doi:10.3724/SP.J.1263.2012.00061. ISSN 1671-5411. PMID 22783324.
  43. ↑ Ocon, Anthony J.; Messer, Zachary R.; Medow, Marvin S.; Stewart, Julian M. (2012). "Increasing orthostatic stress impairs neurocognitive functioning in chronic fatigue syndrome with postural tachycardia syndrome". Clinical Science (London, England : 1979). 122 (5): 227–238. doi:10.1042/CS20110241. ISSN 0143-5221. PMC 3368269. PMID 21919887.
  44. ↑ Ross, Amanda J.; Medow, Marvin S.; Rowe, Peter C.; Stewart, Julian M. (September 3, 2013). "What is brain fog? An evaluation of the symptom in postural tachycardia syndrome". Clinical Autonomic Research. 23 (6): 305–311. doi:10.1007/s10286-013-0212-z. ISSN 0959-9851. PMID 23999934.
  45. ↑ Tomljenovic, Lucija; Colafrancesco, Serena; Perricone, Carlo; Shoenfeld, Yehuda (March 13, 2014). "Postural Orthostatic Tachycardia With Chronic Fatigue After HPV Vaccination as Part of the "Autoimmune/Auto-inflammatory Syndrome Induced by Adjuvants"". Journal of Investigative Medicine High Impact Case Reports. 2 (1). doi:10.1177/2324709614527812. ISSN 2324-7096. PMID 26425598.
  46. ↑ Reynolds, G. K.; Lewis, D.P.; Richardson, A.M.; Lidbury, B.A. (November 29, 2013). "Comorbidity of postural orthostatic tachycardia syndrome and chronic fatigue syndrome in an Australian cohort". Journal of Internal Medicine. 275 (4): 409–417. doi:10.1111/joim.12161. ISSN 0954-6820.
  47. ↑ Wise, Shelby; Ross, Amanda; Brown, Abigail; Evans, Meredyth; Jason, Leonard (November 4, 2015). "An assessment of fatigue in patients with postural orthostatic tachycardia syndrome". Journal of Health Psychology. 22 (6): 733–742. doi:10.1177/1359105315613624. ISSN 1359-1053.
  48. ↑ Roerink, M.E.; Lenders, J.W.M; Schmits, I.C.; Pistorius, A.; Knoop, H.; van der Meer, J.W.M. (2016). "Is Postural Orthostatic Tachycardia a Useful Diagnostic Marker in Chronic Fatigue Syndrome Patients?". Journal of Psychosomatic Research. 85: 78. doi:10.1016/j.jpsychores.2016.03.193. ISSN 0022-3999.
  49. ↑ Roerink, M. E.; Lenders, J. W.M.; Schmits, I.C.; Pistorius, A.M.A.; Smit, J.W.; Knoop, H.; van der Meer, J.W.M. (October 2, 2016). "Postural orthostatic tachycardia is not a useful diagnostic marker for chronic fatigue syndrome". Journal of Internal Medicine. 281 (2): 179–188. doi:10.1111/joim.12564. ISSN 0954-6820.
  50. ↑ Strassheim, Victoria; Welford, Jenny; Ballantine, Rob; Newton, Julia L. (December 2018). "Managing fatigue in postural tachycardia syndrome (PoTS): The Newcastle approach". Autonomic Neuroscience. 215: 56–61. doi:10.1016/j.autneu.2018.02.003.
  51. ↑ Zadourian, Adena; Doherty, Taylor A.; Swiatkiewicz, Iwona; Taub, Pam R. (June 15, 2018). "Postural Orthostatic Tachycardia Syndrome: Prevalence, Pathophysiology, and Management". Drugs. 78 (10): 983–994. doi:10.1007/s40265-018-0931-5. ISSN 0012-6667.
  52. ↑ "Managing Orthostatic Intolerance". SolveCFS on YouTube. September 1, 2010.
  53. ↑ Pavlik, Daniel; Agnew, Donna; Stiles, Lauren; Ditoro, Rachel (2016). "Recognizing postural orthostatic tachycardia syndrome". JAAPA: official journal of the American Academy of Physician Assistants. 29 (4): 17–23. doi:10.1097/01.JAA.0000481398.76099.09. ISSN 1547-1896. PMID 26967958.
  54. ↑ Johnson, Cort (July 4, 2016). "The Exercise Intolerance in POTS, ME/CFS and Fibromyalgia Explained? - Health Rising". Health Rising. Retrieved August 16, 2018.

postural orthostatic tachycardia syndrome (POTS) - A form of orthostatic intolerance where the cardinal symptom is excessive tachycardia due to changing position (e.g. from lying down to sitting up).

See postural orthostatic tachycardia syndrome.

postural orthostatic tachycardia syndrome (POTS) - A form of orthostatic intolerance where the cardinal symptom is excessive tachycardia due to changing position (e.g. from lying down to sitting up).

An unusually rapid heart beat. Can be caused by exercise or illness. A symptom of postural orthostatic tachycardia syndrome (POTS).[1] (Learn more: www.heart.org)

tachycardia An unusually rapid heart beat. Can be caused by exercise or illness. A symptom of postural orthostatic tachycardia syndrome (POTS). (Learn more: www.heart.org)

lying on the back or with the face upward[2]

supine lying on the back or with the face upward

(HR) - the number of times the heart beats within a certain time period, usually a minute[3]

heart rate (HR) - the number of times the heart beats within a certain time period, usually a minute

orthostatic intolerance (OI) - The development of symptoms when standing upright, where symptoms are relieved upon reclining. Patients with orthostatic intolerance have trouble remaining upright for more than a few seconds or a few minutes, depending upon severity. In severe orthostatic intolerance, patients may not be able to sit upright in bed. Orthostatic intolerance is often a sign of dysautonomia. There are different types of orthostatic intolerance, including postural orthostatic tachycardia syndrome (POTS).

enterovirus A genus of RNA viruses which typically enter the body through the respiratory or gastrointestinal systems and sometimes spread to the central nervous system or other parts of the body, causing neurological, cardiac, and other damage. Since the first reports of myalgic encephalomyelitis (ME), enteroviruses have been suspected as a cause of ME. Enteroviruses have also been implicated as the cause of Type I diabetes, congestive heart failure, and other conditions. Enteroviruses include poliovirus, coxsackieviruses, and many others. New enteroviruses and new strains of existing enteroviruses are continuously being discovered. (Learn more: viralzone.expasy.org)

postural orthostatic tachycardia syndrome (POTS) - A form of orthostatic intolerance where the cardinal symptom is excessive tachycardia due to changing position (e.g. from lying down to sitting up).

the condition of being dizzy or on the verge of fainting[4]

lightheadedness the condition of being dizzy or on the verge of fainting

autoantibody An antibody that works against the body's own antigens, a hallmark of autoimmune diseases. Autoantibodies are the opposite of an antibodies.

See ME/CFS.

Centers for Disease Control and Prevention (CDC) - The Centers for Disease Control and Prevention is a U.S. government agency dedicated to epidemiology and public health. It operates under the auspices of the Department of Health and Human Services.

See Centers for Disease Control and Prevention.

See Canadian consensus criteria.

Canadian Consensus Criteria (CCC) - A set of diagnostic criteria used to diagnose ME/CFS, developed by a group of practicing ME/CFS clinicians in 2003. The CCC is often considered to be the most complex criteria, but possibly the most accurate, with the lowest number of patients meeting the criteria. Led to the development of the International Consensus Criteria (ICC) in 2011.

International Consensus Criteria (ICC) - A set of diagnostic criteria, based on the Canadian Consensus Criteria, that argued for the abandonment of the term "chronic fatigue syndrome" and encouraged the sole use of the term "myalgic encephalomyelitis".

See International Consensus Criteria.

tachycardia An unusually rapid heart beat. Can be caused by exercise or illness. A symptom of postural orthostatic tachycardia syndrome (POTS). (Learn more: www.heart.org)

chronic fatigue (CF) - Persistent and abnormal fatigue is a symptom, not an illness. It may be caused by depression, multiple sclerosis, fibromyalgia, chronic fatigue syndrome or many other illnesses. The term "chronic fatigue" should never be confused with the disease chronic fatigue syndrome.

pacing The practice of staying within one's "energy envelope" or personal limit by combining periods of activity with periods of rest or avoiding exerting beyond a certain level. ME/CFS patients use pacing to avoid or reduce post-exertional malaise (PEM). Some patients use a heart rate monitor to help with pacing.

myalgic encephalomyelitis (M.E.) - A disease often marked by neurological symptoms, but fatigue is sometimes a symptom as well. Some diagnostic criteria distinguish it from chronic fatigue syndrome, while other diagnostic criteria consider it to be a synonym for chronic fatigue syndrome. A defining characteristic of ME is post-exertional malaise (PEM), or post-exertional neuroimmune exhaustion (PENE), which is a notable exacerbation of symptoms brought on by small exertions. PEM can last for days or weeks. Symptoms can include cognitive impairments, muscle pain (myalgia), trouble remaining upright (orthostatic intolerance), sleep abnormalities, and gastro-intestinal impairments, among others. An estimated 25% of those suffering from ME are housebound or bedbound. The World Health Organization (WHO) classifies ME as a neurological disease.

myalgic encephalomyelitis (M.E.) - A disease often marked by neurological symptoms, but fatigue is sometimes a symptom as well. Some diagnostic criteria distinguish it from chronic fatigue syndrome, while other diagnostic criteria consider it to be a synonym for chronic fatigue syndrome. A defining characteristic of ME is post-exertional malaise (PEM), or post-exertional neuroimmune exhaustion (PENE), which is a notable exacerbation of symptoms brought on by small exertions. PEM can last for days or weeks. Symptoms can include cognitive impairments, muscle pain (myalgia), trouble remaining upright (orthostatic intolerance), sleep abnormalities, and gastro-intestinal impairments, among others. An estimated 25% of those suffering from ME are housebound or bedbound. The World Health Organization (WHO) classifies ME as a neurological disease.

somatic symptom disorder A psychiatric term to describe an alleged condition whereby a person's thoughts somehow cause physical symptoms. The actual existence of such a condition is highly controversial, due to a lack of scientific evidence. It is related to other psychiatric terms, such as "psychosomatic", "neurasthenia", and "hysteria". Older terms include "somatization", "somatoform disorder", and "conversion disorder". Such terms refer to a scientifically-unsupported theory that claims that a wide range of physical symptoms can be created by the human mind, a theory which has been criticized as "mind over matter" parapsychology, a pseudoscience.

Retrieved from "https://me-pedia.org/w/index.php?title=Postural_orthostatic_tachycardia_syndrome&oldid=243481"